Pharmacodynamics and Pharmacokinetics of Different Modes of Rocuronium Administration
Rocuronium (Org 9426), which has recently been introduced in clinical practice, is the 2-morpholino, 3-hydroxy, 16N-allyl-pyrrolidino derivative of vecuronium. In contrast to vecuronium no pharmacologically active metabolites of this compound have been found in man. Its neuromuscular blocking potency is about 7 times less than that of vecuronium [1,2]. Rocuronium has intermediate duration of action, and after several maintenance doses of rocuronium no tendency toward cumulation was shown [3,4]. Therefore, rocuronium might be suitable for prolonged administration in critically ill patients (ICU-patients). However, neuromuscular blocking agents are developed and tested for use once or twice in a life-time, usually in surgical patients. No information has been available so far on the administration of rocuronium in critically ill patients .
KeywordsSurgical Patient Neuromuscular Blocking Agent Infusion Group Peripheral Nerve Stimulator Rocuronium Bromide
Unable to display preview. Download preview PDF.
- 5.Sparr HJ, Khuenl-Brady KS, Eriksson LI (1994) Pharmacodynamics and pharmacokinetics of rocuronium following continuous infusion in patients during intravenous anaesthesia. Eur J Anaesth 11 (Suppl. 9): 63–65Google Scholar
- 9.Wagner JG (1979) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications Inc, Hamilton Illinois, USAGoogle Scholar
- 10.Wierda JMKH, Kleef UW, Lambalk LM, Kloppenburg WD, Agoston S (1991) The pharmacokinetics and pharacodynamics of Org 9426, a new non depolarazing neurmuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anaesth 38:435–435Google Scholar
- 15.Pollard BJ (1993) Neuromuscular blocking agents in intensive care. Intensive Care Med 1993;19 (Suppl 2):536–39Google Scholar
- 17.Caldwell JE, Szenohradszky J, Segredo V, Wright PMC, McLoughlin C, Sharma ML, Gruenke LD, Fisher DM, Miller RD (1994) The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. J Pharmacol Exp Ther 270:1216–1222PubMedGoogle Scholar